S. 4885

119 S4885 IS: Shandra Eisenga Human Cell and Tissue Product Safety Act
 U.S. Senate
 2026-06-24
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 II  119th CONGRESS  2d Session  S. 4885  IN THE SENATE OF THE UNITED STATES   June 24, 2026   Mr. Peters  (for himself and  Mr. Marshall ) introduced the following bill; which was read twice and referred to the  Committee on Health, Education, Labor, and Pensions    A BILL
To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
1.
Short title
This Act may be cited as the   Shandra Eisenga Human Cell and Tissue Product Safety Act  .
2.
Definitions
In this Act:
(1)
Human cell and tissue product
The terms  human cell and tissue product  and  human cell and tissue products  have the meaning given the term  human cells, tissues, or cellular or tissue-based products  in section 1271.3(d) of title 21, Code of Federal Regulations (or successor regulations).
(2)
Secretary
The term  Secretary  means the Secretary of Health and Human Services.
(3)
Tissue Reference Group
The term  Tissue Reference Group  means the Tissue Reference Group of the Food and Drug Administration.
3.
Human cell and tissue products transplant public awareness campaign
The Secretary shall support the development and dissemination of educational materials to inform health care professionals and other appropriate professionals about issues surrounding—
(1)
organ, tissue, and eye donation, including evidence-based methods to approach patients and their families;
(2)
the availability of any donor screening tests; and
(3)
other relevant aspects of donation.
4.
Civil penalties for violation of requirements for human cell and tissue products
Section 368 of the Public Health Service Act ( 42 U.S.C. 271 ) is amended by adding at the end the following:
(d)
(1)
Any person who, on or after the date of the enactment of the  Shandra Eisenga Human Cell and Tissue Product Safety Act , violates a requirement of subpart C or D of section 1271 of title 21, Code of Federal Regulations (or successor regulations), with respect to human cell or tissue products regulated under section 361 shall be liable to the United States for a civil penalty in an amount not to exceed the sum of—
(A)
(i)
$20,000 for each violation; and
(ii)
in the case of a violation that continues after the Secretary provides written notice to such person, $20,000 for each subsequent day on which the violation continues; and
(B)
an amount equal to the retail value of the human cell and tissue products that are the subject of the violation.
(2)
The total civil penalty under paragraph (1) may not exceed $10,000,000 for all such violations adjudicated in a single proceeding.
(3)
In this subsection, the term  human cell and tissue products  has the meaning given the term  human cells, tissues, or cellular or tissue-based products  in section 1271.3(d) of title 21, Code of Federal Regulations (or successor regulations).
 .
5.
Streamlining regulatory oversight of human cell and tissue products
(a)
Information on human cell and tissue products
(1)
Website
The Secretary, acting through the Commissioner of Food and Drugs, shall publish on the public website of the Food and Drug Administration—
(A)
educational materials about the Tissue Reference Group; and
(B)
best practices for obtaining a timely, accurate recommendation regarding human cell and tissue products from the Tissue Reference Group.
(2)
Public information
Not later than 1 year after the date of the enactment of this Act, and annually for the subsequent 3 years, the Secretary, acting through the Commissioner of Food and Drugs, shall publish on the public website of the Food and Drug Administration—
(A)
the number of human cell and tissue establishments that registered with the Food and Drug Administration on or after January 1, 2019;
(B)
the number of inspections conducted by the Food and Drug Administration of human cell and tissue establishments on or after January 1, 2019, including a comparison of the number of inspections for blood establishments with the number of inspections for such human cell and tissue establishments;
(C)
the number and type of inquiries to the Tissue Reference Group in the preceding year; and
(D)
the average response time for submissions to the Tissue Reference Group in the preceding year, including average initial and final response time.
(3)
Education
The Secretary, acting through the Commissioner of Food and Drugs, shall, with respect to the regulation of human cell and tissue products—
(A)
provide information to relevant stakeholders, including industry, tissue establishments, academic health centers, biomedical consortia, research organizations, and patients; and
(B)
conduct workshops and other interactive and educational sessions for such stakeholders to help support regulatory predictability and scientific advancement, as appropriate.
(b)
Human cell and tissue product scientific and regulatory updates
Section 3205 of the Food and Drug Omnibus Reform Act of 2022 (title III of division FF of  Public Law 117–328 ) is amended by striking  best practices  and all that follows through  other cellular therapies  and inserting  best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue-, and cellular-based medical products (and the latest scientific information about such products), namely, stem cell and other cellular therapies .
(c)
Public docket
Not later than 60 days after the date of the enactment of this Act, the Secretary shall establish a public docket to receive written comments related to—
(1)
the approaches recommended for discussion during the public workshop described in section 3205 of the Food and Drug Omnibus Reform Act of 2022 (title III of division FF of  Public Law 117–328 ); and
(2)
modernizing the regulation of human cell and tissue products, including considerations associated with assessing minimal manipulation and homologous use (as such terms are defined in section 1271.3 of title 21, Code of Federal Regulations (or successor regulations)) of human cell and tissue products.
(d)
Report to Congress
Not later than September 30, 2026, the Secretary shall summarize the approaches discussed in the public workshop described in section 3205 of the Food and Drug Omnibus Reform Act of 2022 (title III of division FF of  Public Law 117–328 ) and the public docket described in subsection (c), and develop recommendations regarding the regulation of human cell and tissue products, including provisions under sections 1271.10(a) and 1271.3 of title 21, Code of Federal Regulations, taking into account—
(1)
regulatory burden;
(2)
scientific developments;
(3)
access to human cell and tissue products regulated under section 361 of the Public Health Service Act ( 42 U.S.C. 264 ); and
(4)
protecting public health.